ALLISON DANIELS: Open Payments
NPI 1235706805 · NEW HAVEN, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$776 in 44 payments from 15 companies in 2025. Trend: 2023 $1,011 · 2024 $1,506 · 2025 $776
Food & beverage: $776
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics | 4 | $174 |
| ABBVIE INC. | 15 | $163 |
| Corium, LLC | 7 | $109 |
| Lilly USA, LLC | 3 | $53 |
| Novo Nordisk Inc | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
| GlaxoSmithKline, LLC. | 1 | $20 |
Products named: Korlym, Azstarys, VRAYLAR, JARDIANCE, Ozempic, CAPLYTA, QULIPTA, UBRELVY.
Industry payments across IN — which companies pay providers there.
